Drug Trial Radar · NCT06739213
A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma
Last checked: Nov 20, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Jan 31, 2025
Primary completion
Jan 31, 2027
Study completion Jan 13, 2028
Sponsor
- Lead sponsor
- Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, controlled, open-label, multicenter, Phase II clinical study designed to evaluate the efficacy and safety of SYHA1813 compared to investigators' choice in participants with recurrent or progressive high-grade meningioma.
Conditions
- Recurrent or Progressive High Grade Meningioma
Interventions
SYHA1813Drug
The starting dose of SYHA1813 is 20mg QD
Investigator's Choice TreatmentDrug
Investigator's Choice Treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- the Progression-free survival (PFS) at 6-month(PFS-6)as evaluated by investigator (RANO-meningioma)Time frame: Up to approximately 3years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.